UNSPSC 51402201: Pagoclone

This classification denotes an anxiolytic with the molecular formula C23H22ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 38VAG2SA33, chemically known as 2-(7-chloro-2-naphthyridin-1,8-yl)-3-(5-methyl-2-oxohexyl)isoindolin-1-one but generally known as pagoclone, which bears US NIH Compound Identifier 131664. European Medicines Agency schedules Pagoclone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09586MIG.

UNSPSC 51402201 Pagoclone is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems for community health support, a pharmaceutical and harm-reduction product line unrelated to pagoclone, a selective dopamine D1-receptor agonist used in research contexts. The mismatch suggests either a tagging error in the procurement system or a misalignment between the UNSPSC taxonomy and how issuing bodies are classifying their buys.

The Seminole County solicitation is the only recent state or local opportunity available under this code. That single IFB calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to Sanford, Florida, and a response deadline of July 26, 2023. The procurement requires E-Verify compliance, drug-free workplace certification, and standard insurance coverage; vendors must include shipping costs in their bid. Given the absence of additional recent opportunities and the evident mismatch between the code's nominal scope and actual buy, the code shows little relevant activity for business development targeting genuine pagoclone procurement in state and local markets.